STAT+: A widely anticipated ALS drug wouldn’t be cost effective if priced the same as an older rival

Amid growing demand for ALS treatments, a preliminary analysis finds an experimental medicine that may be approved later this year by U.S. regulators would not be cost effective if it carries the same high price as an older medication.

The analysis examined Radicava, an intravenous medicine that was approved five years ago and will soon be available as a tablet, with a medication that is currently under review by the Food and Drug Administration. Developed by Amylyx Pharmaceuticals, the newer drug is also a tablet and has sparked optimism among ALS patient groups that are clamoring for useful treatments.

Continue to STAT+ to read the full story…